Form 4: Monopar Therapeutics COO Andrew Cittadine Reports Stock Transactions

Monopar Therapeutics' Chief Operating Officer, Andrew Cittadine, acquired 1,790 shares of common stock and disposed of 721 shares to cover taxes related to vesting restricted stock units on December 31, 2024.

Summary

• Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, reported transactions involving the company's stock on December 31, 2024.
• He acquired 1,790 shares of common stock through the vesting of restricted stock units.
• Additionally, 721 shares were disposed of to cover tax obligations related to the vesting of these units.
• Following these transactions, Mr. Cittadine directly owns 40,938 shares of Monopar Therapeutics common stock.
• The transactions also involved the vesting of 1,790 restricted stock units, leaving him with 11,074 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as this is a routine transaction related to executive compensation. There is no indication of positive or negative sentiment from the document itself.

Positives

• The vesting of restricted stock units indicates that Mr. Cittadine is meeting the conditions of his equity grants.
• The acquisition of 1,790 shares increases his direct ownership in the company.

Negatives

• The disposal of 721 shares, while for tax purposes, reduces his overall shareholding.

Risks

• The document does not indicate any specific risks.
• However, insider transactions can sometimes be perceived negatively by the market if not understood.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders conduct transactions in their company's stock. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The vesting of restricted stock units is a common form of equity compensation for executives in publicly traded companies, including those in the biotechnology sector like Monopar Therapeutics.
• The tax-related disposal of shares is also a standard practice when restricted stock units vest.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use similar equity compensation plans for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation practices.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Monopar Therapeutics, insider trading, Form 4, restricted stock units, stock transactions, Andrew Cittadine, equity compensation